OncoMatch/Clinical Trials/NCT06008288
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Is NCT06008288 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies JAB-21822 for kras p.g12c.
Treatment: JAB-21822 — Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Tumor Agnostic
Biomarker criteria
Required: KRAS p.G12C mutation
KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic reagents or clinical trial assay (CTA) methods
Prior therapy
Must have received: gemcitabine-based chemotherapy — pancreatic cancer
Patients with pancreatic cancer must have progressed or been intolerant to prior gemcitabine-based chemotherapy regimens
Must have received: FOLFIRINOX or mFOLFIRINOX or NALIRIFOX — pancreatic cancer
Patients with pancreatic cancer must have progressed or been intolerant to prior ... FOLFIRINOX/mFOLFIRINOX/NALIRIFOX treatment
Must have received: systemic therapy — other types of solid tumors
Patients with other types of solid tumors must have progressed or been intolerant to prior systemic therapies and lack satisfactory alternative treatment options
Cannot have received: KRAS G12C inhibitor
Previously received a KRAS G12C inhibitor
Lab requirements
Cardiac function
Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) <470 ms calculated from 3 electrocardiograms
Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify